Royalty Pharma Plc (RPRX)
69.31
+0.34
(+0.49%)
USD |
NASDAQ |
Nov 13, 16:00
69.30
0.00 (0.00%)
After-Hours: 19:59
Royalty Pharma Enterprise Value : 41.90B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 41.90B |
| November 12, 2026 | 41.75B |
| November 11, 2026 | 42.21B |
| November 10, 2026 | 41.96B |
| November 09, 2026 | 41.66B |
| November 06, 2026 | 41.00B |
| November 05, 2026 | 41.13B |
| November 04, 2026 | 41.12B |
| November 03, 2026 | 40.60B |
| November 02, 2026 | 40.66B |
| October 30, 2026 | 40.95B |
| October 29, 2026 | 40.39B |
| October 28, 2026 | 39.90B |
| October 27, 2026 | 40.10B |
| October 26, 2026 | 39.87B |
| October 23, 2026 | 39.47B |
| October 22, 2026 | 39.42B |
| October 21, 2026 | 38.71B |
| October 20, 2026 | 38.75B |
| October 19, 2026 | 37.87B |
| October 16, 2026 | 38.18B |
| October 15, 2026 | 37.58B |
| October 14, 2026 | 37.30B |
| October 13, 2026 | 36.22B |
| October 12, 2026 | 36.76B |
| Date | Value |
|---|---|
| October 09, 2026 | 36.38B |
| October 08, 2026 | 36.06B |
| October 07, 2026 | 36.31B |
| October 06, 2026 | 36.16B |
| October 05, 2026 | 36.26B |
| October 02, 2026 | 36.48B |
| October 01, 2026 | 36.69B |
| September 30, 2026 | 37.02B |
| September 29, 2026 | 37.03B |
| September 28, 2026 | 37.10B |
| September 25, 2026 | 37.02B |
| September 24, 2026 | 37.06B |
| September 23, 2026 | 36.78B |
| September 22, 2026 | 37.16B |
| September 21, 2026 | 37.13B |
| September 18, 2026 | 37.11B |
| September 17, 2026 | 37.35B |
| September 16, 2026 | 37.14B |
| September 15, 2026 | 37.14B |
| September 14, 2026 | 37.40B |
| September 11, 2026 | 37.20B |
| September 10, 2026 | 37.27B |
| September 09, 2026 | 38.09B |
| September 08, 2026 | 38.09B |
| September 04, 2026 | 39.59B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 408.57B |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
| Veru, Inc. | 12.53M |
| Johnson & Johnson | 715.26B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.64M |
| Revenue (Quarterly) | 690.10M |
| Total Expenses (Quarterly) | 545.43M |
| EPS Diluted (Quarterly) | 0.3238 |
| Gross Profit Margin (Quarterly) | 99.82% |
| Profit Margin (Quarterly) | 38.64% |
| Earnings Yield | 2.22% |
| Operating Earnings Yield | 4.71% |
| Normalized Earnings Yield | 2.584 |